P
Patrick P. Zarrinkar
Researcher at Ambit Biosciences
Publications - 25
Citations - 7178
Patrick P. Zarrinkar is an academic researcher from Ambit Biosciences. The author has contributed to research in topics: Kinase & Midostaurin. The author has an hindex of 16, co-authored 25 publications receiving 6701 citations. Previous affiliations of Patrick P. Zarrinkar include Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
A quantitative analysis of kinase inhibitor selectivity.
Mazen W. Karaman,Sanna Herrgard,Daniel K. Treiber,Paul Gallant,Corey E. Atteridge,Brian T. Campbell,Katrina W Chan,Pietro Ciceri,Mindy I. Davis,Philip T. Edeen,Raffaella Faraoni,Mark Floyd,Jeremy P. Hunt,Daniel J Lockhart,Zdravko V. Milanov,Michael J Morrison,Gabriel Pallares,Hitesh K. Patel,Stephanie Pritchard,Stephanie Pritchard,Lisa M. Wodicka,Patrick P. Zarrinkar +21 more
TL;DR: This work presents interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome and introduces the concept of a selectivity score as a general tool to quantify and differentiate the observed interaction patterns.
Journal ArticleDOI
A small molecule-kinase interaction map for clinical kinase inhibitors.
Miles A. Fabian,William H. Biggs,Daniel K. Treiber,Corey E. Atteridge,Mihai Azimioara,Mihai Azimioara,Michael G. Benedetti,Michael G. Benedetti,Todd A. Carter,Pietro Ciceri,Philip T. Edeen,Mark Floyd,Julia M. Ford,Margaret Galvin,Jay L Gerlach,Jay L Gerlach,Robert M. Grotzfeld,Sanna Herrgard,Darren E. Insko,Michael A Insko,Andiliy G. Lai,Jean-Michel Lélias,Shamal A. Mehta,Zdravko V. Milanov,Anne Marie Velasco,Lisa M. Wodicka,Hitesh K. Patel,Patrick P. Zarrinkar,David J. Lockhart +28 more
TL;DR: An efficient way to determine kinase inhibitor specificity by measuring binding of small molecules to the ATP site of kinases is described, which represents a systematic small molecule-protein interaction map for clinical compounds across a large number of related proteins.
Journal ArticleDOI
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer
John B. Welsh,Patrick P. Zarrinkar,Lisa M. Sapinoso,Suzanne G. Kern,Cynthia Behling,Bradley J. Monk,David J. Lockhart,Robert A. Burger,Garret M. Hampton +8 more
TL;DR: This study uses oligonucleotide microarrays with probe sets complementary to >6,000 human genes to identify genes whose expression correlated with epithelial ovarian cancer and demonstrates the rapidity with which large amounts of expression data can be generated.
Journal ArticleDOI
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith,Qi Wang,Chen-Shan Chin,Sara Salerno,Lauren E. Damon,Mark J. Levis,Alexander E. Perl,Kevin Travers,Susana Wang,Jeremy P. Hunt,Jeremy P. Hunt,Patrick P. Zarrinkar,Patrick P. Zarrinkar,Eric E. Schadt,Eric E. Schadt,Andrew Kasarskis,Andrew Kasarskis,John Kuriyan,Neil P. Shah +18 more
TL;DR: It is demonstrated that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML and AC220-resistant FLT 3 kinase domain mutants represent high-value targets for futureFLT3 inhibitor development efforts.
Journal ArticleDOI
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar,Ruwanthi N. Gunawardane,Merryl D. Cramer,Michael F. Gardner,Daniel Brigham,Barbara Belli,Mazen W. Karaman,Keith W. Pratz,Gabriel Pallares,Qi Chao,Kelly G. Sprankle,Hitesh K. Patel,Mark J. Levis,Robert C. Armstrong,Joyce James,Shripad Bhagwat +15 more
TL;DR: The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clinical FLT3 inhibitor.